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Sirolimus treatment reduced dependence on octreotide
and frequent feeding in 4 infants with CHI in a recent
study [1]. We report our experience in a 1 year-old boy
with presumed diffuse disease due to a de novo hetero-
zygous ABCC8 missense mutation (p.D1506E).
This macrosomic infant (term birth weight 5.676kg)
presented with hypoglycaemia in the first hours of life.
Critical sample results were consistent with CHI (blood
glucose 0.9mmol/L, insulin 41mU/L, free fatty acids
0.2mmol/L[RR 0.1-0.6]). The family history was signifi-
cant for type 2 diabetes in both grandmothers, and CHI
in his maternal second cousin. No ABCC8 missense
mutation was identified in either parent or his second
cousin.
Initial management included intravenous glucose
(12mg/kg/min) and glucagon infusions. Maximal dose
diazoxide (20mg/kg/day for 5 days) was ineffective so
subcutaneous octreotide infusion was initiated (26mcg/
kg/day). At discharge from hospital (age 10 weeks) he
was overweight (height SDS 1.11, weight SDS 3.1),
receiving octreotide 27mcg/kg/day, nocturnal gastro-
stomy Polyjoule® feeds (equivalent to 11mg/kg/min glu-
cose) plus 3-hourly daytime bolus feeds.
Sirolimus (0.5mg/m2/day) was added at age 7 months
because of continued weight gain and intermittent mild
hypoglycaemia while receiving octreotide 37mcg/kg/day.
The dose was increased to 6mg/m2/day, aiming for
trough levels 15-20ng/ml. After 3 months, the octreotide
dose has stabilised (36mcg/kg/day) and the intensity of
feeds has been reduced (3.5mg/kg/minute glucose over-
night), resulting in weight loss; however, he has also
developed linear growth failure (height velocity 6cm/year
over 3 months). At 1 year of age his length and weight
SDS are 0.48 and 1.21 respectively, and he is develop-
mentally appropriate for age. Apart from one mild epi-
sode of respiratory syncytial virus, he has had no
significant illnesses during sirolimus treatment.
In conclusion, treatment with sirolimus has improved
our patient’s blood glucose concentrations, decreased
his dependence on hypercaloric nocturnal continuous
feeds and decreased his weight gain; however the burden
of care remains more significant than reported in the 4
published cases, 2 of whom had heterozygous mutations
in ABCC8. The combination of high-dose octreotide
and sirolimus may not be sustainable long-term in view
of their likely combined contribution to his growth fail-
ure and the potential for immunosuppression due to
sirolimus.
Written informed consent was obtained from the
patient’s parent or guardian for publication of this Case
report (and any accompanying images). A copy of the writ-
ten consent is available for review by the Editor-in-Chief of
this journal.
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